We have set up a clear vision for Nordmark's future. This definition allows us to invest specifically in the skills and technology needed in our focus areas. Dr Jörn Tonne, CEO and Managing Director
We have set up a clear vision for Nordmark's future. This definition allows us to invest specifically in the skills and technology needed in our focus areas.
Dr Jörn Tonne, CEO and Managing Director
Quality products, service material and high delivery capacity: our mix for ideal patient care. Volker Kahrmann, Head of Marketing
Quality products, service material and high delivery capacity: our mix for ideal patient care.
Volker Kahrmann, Head of Marketing
Innovation plays a prominent role for us. On the one hand, in the further development and optimisation of our existing business. On the other hand, we are developing into new fields, such as hormone replacement therapy and the isolation and proliferation of stem cells. Dr Jörn Tonne, CEO and Managing Director
Innovation plays a prominent role for us. On the one hand, in the further development and optimisation of our existing business. On the other hand, we are developing into new fields, such as hormone replacement therapy and the isolation and proliferation of stem cells.
06/03/2026
At the initiative of the German Pharmaceutical Association, we were guests at the Federal Ministry for Economic Affairs and Energy (BMWE) in Berlin
Read more
05/20/2026
Biopharmaceutical know-how is concentrated here in Uetersen–from development to approval. Why all this? For patients like Lisa!
03/09/2026
07/12/2021
Explaining complex issues in an understandable way - Our path to the new video
06/04/2021
There are over 18,600 study paths and more than 450 apprenticeships in Germany. Find the needle in the haystack!
03/24/2021
One of the most important construction projects on Nordmark's site is called 'BIBITEC'. Currently, an area of the existing biotechnology centre is…
01/29/2021
In the course of reorganisation the entire pharmaceutical operations of Nordmark Arzneimittel GmbH & Co. KG was tranferred to Nordmark Pharma GmbH on…